about
Next-generation sequencing: advances and applications in cancer diagnosisThe next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseMale breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry.Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.SELDI-TOF serum proteomics and breast cancer: which perspective?Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expressionProteomic profile in familial breast cancer patients.Body mass index and serum proteomic profile in breast cancer and healthy women: a prospective study.Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutationMicroRNA expression profiling in male and female familial breast cancer.KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorBRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.Immunoprofile from tissue microarrays to stratify familial breast cancer patientsMitochondria and familial predisposition to breast cancer."Sequencing-grade" screening for BRCA1 variants by oligo-arrays.Phosphatidylinositol 3-kinase in breast cancer: where from here?Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.Molecular pathways and related target therapies in liver carcinoma.Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancerSULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.Identification of tumor evolution patterns by means of inductive logic programming.Expression of base excision repair key factors and miR17 in familial and sporadic breast cancerThe dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.Microsatellite instability (MSI) as genomic markers in endometrial cancer: toward scientific evidences.Update on capecitabine alone and in combination regimens in colorectal cancer patients.Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidenceBRCAness: a deeper insight into basal-like breast tumors.Male breast cancer: genetics, epigenetics, and ethical aspects.The value of new high-throughput technologies for diagnosis and prognosis in solid tumors.Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
P50
Q28073891-90E49649-8428-4343-BA5A-AAF1FC14984FQ30384301-9D1B49A0-2C90-4B8F-9D5E-433E73E6DAF4Q31043651-3471A3F7-CFCE-481D-966E-1209AEAFBE8AQ33307029-8062FBF3-1E16-4059-9F68-CE2C59BD8F41Q33327868-BEB57E46-F41B-4AE9-B163-DD5F2EF999FFQ33393365-73C70B71-D58A-4CB7-9E28-B77BDF84B3EBQ33728131-483B0BE6-C4BC-4A90-927C-5B2D8F8BBA3BQ34046731-AF7B1D81-4F2E-40C0-B961-A770AD2564EFQ34272649-ECBB619E-5711-40F4-9542-52BB543C1D83Q34480212-D0390DA0-6AD0-44DA-8BB0-5136EA69CDB6Q34505013-1DEB29A9-81E6-4A9D-81AA-E0BC83525DA3Q34551543-09EB35DB-E33A-4D6D-B422-29DC8B49F8DDQ34599527-45F7CF4B-57C5-431B-8AE0-77AB310ADF63Q34687031-EA2B8509-7A38-4550-B28B-BAB24EBBD925Q34748747-5955A65B-1478-4ED8-B6CF-A8CA528355FDQ35041273-717E28FA-4F8F-4BBD-BD9A-81CABF33CEF9Q35999309-7F4D88F7-615C-41BC-9613-2301A35A9EE9Q36029740-8C35C9B2-E43E-4CB5-BEA2-FDE5F1D73C74Q36413928-0E7AE860-CB16-4043-8561-9AE91BB2A9EEQ36877040-9935DFDE-8D13-4E0F-8DF6-A1971D8CEE7CQ36975142-79AD54A1-D49F-4F26-9D9D-A374326D780FQ36975572-BD6B88C8-36D5-44EB-BDF2-BD0B32D44E3CQ37013255-FD1B504D-F649-4613-8BC8-52990085BEA6Q37017984-D3437D3E-F377-4629-8AD8-EEE4FBBD364EQ37043828-4112C8AD-70B6-49C6-B414-35AABE7B8097Q37294547-A04361BC-DBF2-4310-B468-41F493CD6A5FQ37315121-D2E8441E-5834-4840-B0EE-D30F498AE99FQ37318341-E12DF05A-913D-4EE8-9674-0A5117E86E62Q37620662-63FBA617-4067-45E4-A5A9-3ED6DBD018F4Q37687027-9FB70D27-3836-4E2F-BC46-FBDDB4D3C48DQ37687527-C6344DC1-8A21-49AC-9B9C-D9D633105664Q37697004-1FE920E0-C593-4B39-9308-6249B206AFC0Q37799389-6E51DFB0-50EC-4CDE-8896-C852C275A9F1Q37815612-6B058C70-DBF1-458F-86B9-5F284DA3E804Q37825246-7FFA91CB-F96C-4883-B7F2-539CADDF8E01Q38153181-A6D96847-8DF2-4658-95FD-032BE2DA1764Q38153187-518CA6CF-5F32-407B-A9D9-DF3FC1E08B70Q38216171-F096A016-5749-42CA-8EEF-C76C75A86C6AQ38305006-2028F771-84E5-4353-AF8D-17B50C09799CQ38750988-C6E8A8CD-A315-422F-97D8-BA9D3E25E515
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefania Tommasi
@ast
Stefania Tommasi
@en
Stefania Tommasi
@es
Stefania Tommasi
@nl
Stefania Tommasi
@sl
type
label
Stefania Tommasi
@ast
Stefania Tommasi
@en
Stefania Tommasi
@es
Stefania Tommasi
@nl
Stefania Tommasi
@sl
prefLabel
Stefania Tommasi
@ast
Stefania Tommasi
@en
Stefania Tommasi
@es
Stefania Tommasi
@nl
Stefania Tommasi
@sl
P1053
J-6732-2012
P106
P21
P31
P3829
P496
0000-0002-2157-2978